Taken together, this study first showed that KFXYS has a significant anti-inflammatory effect by inhibiting activation of the NF-κB pathway, and correspondingly reduced TGF-β/MMP-2 associated tissue adhesion, which suggests that KFXYS may be a potential adjunct therapeutic agent for PID, especially in patients with antibiotic resistance. Here, TGFB1 is linked to pelvic inflammatory disease.